noncoval
associ
surfac
transmembran
subunit
envelop
glycoprotein
decor
surfac
human
immunodefici
viru
trimer
spike
serv
target
broadli
neutral
monoclon
antibodi
bnab
involv
primari
step
receptor
coreceptor
bind
envelop
identifi
major
target
nab
howev
antigen
variabl
expos
region
low
immunogen
conserv
domain
impos
great
challeng
identifi
vulner
target
nevertheless
conserv
epitop
identifi
use
antibodi
neutral
sera
bnab
includ
antibodi
direct
receptor
bind
site
coreceptor
bind
site
mainli
third
variabl
region
crystal
structur
resolv
recent
show
protrud
core
extend
structur
divid
three
region
base
residu
stem
crown
residu
residu
number
wrt
loop
highli
antigen
human
previous
recogn
princip
neutral
domain
howev
role
shown
restrict
type
specif
virus
observ
support
extens
sequenc
variat
differ
viral
isol
given
critic
interact
coreceptor
host
cell
convent
must
retain
structur
conserv
element
requir
bind
recent
studi
reveal
domain
possess
conserv
structur
motif
despit
sequenc
variat
often
access
viru
surfac
target
bnab
although
loop
display
high
structur
conserv
yet
degre
cross
reactiv
antibodi
respons
individu
infect
divers
subtyp
vari
substanti
differ
antibodi
respons
loop
shown
primarili
determin
four
amino
residu
crown
gpgq
gpgr
mostli
form
type
ii
interestingli
monoclon
antibodi
mab
isol
nonclad
b
infect
individu
bear
gpgq
tip
display
better
neutral
capac
subtypeb
gpgr
deriv
mab
observ
substanti
studi
show
high
neutral
potenti
mab
deriv
cameroon
subject
infect
virus
harbor
gpgq
subtypeag
crown
immun
studi
carri
rabbit
dna
prime
follow
boost
variou
cholera
toxin
b
ctb
fusion
protein
contain
sequenc
differ
subtyp
ctb
fusion
protein
contain
consensusc
conc
sequenc
gpgq
motif
crown
elicit
highli
potent
neutral
respons
compar
construct
limit
number
mab
gener
far
subtypec
virus
includ
mab
loop
despit
fact
subtypec
account
global
infect
known
human
bnab
clade
b
infect
patient
keep
view
fact
gener
three
human
mab
infect
indian
patient
use
ebv
immort
method
human
hybridoma
technolog
function
analysi
antibodi
gener
studi
reveal
cross
reactiv
bind
neutral
virus
test
total
cultur
well
well
plate
pbmc
deriv
infect
patient
establish
week
cultur
supernat
approxim
transform
well
test
posit
reactiv
tabl
three
heterohybridoma
produc
mab
gener
differ
individu
id
mab
belong
subclass
one
use
lambda
two
kappa
light
chain
gene
interestingli
kappa
light
chain
ab
display
immunoglobulin
heavi
chain
variabl
ighv
gene
usag
ab
show
gene
usag
tabl
complementar
determin
region
heavi
chain
differ
mab
indic
uniqu
tabl
plasma
sampl
patient
recruit
studi
previous
screen
rel
bind
peptid
andrabi
et
al
submit
data
shown
three
sampl
mab
isol
figur
peptid
bind
assay
reveal
cross
reactiv
bind
potenti
ab
plasma
sampl
show
subtypec
specif
bind
order
determin
specif
mab
gener
three
patient
perform
elisa
bind
titrat
mab
recombin
envelop
protein
deriv
peptid
tabl
addit
three
indian
mab
gener
studi
also
test
bind
bnab
isol
subtypeb
infect
individu
live
usa
bind
curv
mab
conc
b
peptid
subtypec
b
jrfl
protein
depict
repres
figur
mab
also
test
seri
peptid
protein
qualiti
control
purpos
maxim
bind
bind
titer
summar
tabl
overal
mab
show
bind
subtypea
c
antibodi
also
react
subtypeb
region
figur
tabl
test
mab
elisa
bind
assay
use
linear
overlap
peptid
encompass
mainli
region
flank
second
constant
third
constant
region
identifi
core
epitop
recogn
found
mab
includ
mab
bind
crown
loop
tabl
bind
ab
deriv
peptid
protein
necessarili
mean
mab
abl
bind
intact
virus
essenti
present
nativ
conform
order
address
possibl
test
mab
bind
subtypec
jrfl
subtypeb
virus
intact
virion
bind
assay
two
virus
jrfl
chosen
experi
basi
sequenc
similar
correspond
conc
b
sequenc
figur
consist
bind
mab
jrfl
deriv
envelop
protein
three
mab
show
differenti
bind
affin
intact
virion
display
high
affin
compar
addit
mab
retain
crossreact
bind
potenti
intact
virus
evid
bind
pattern
figur
experi
valid
test
intact
virion
bind
mab
viru
known
well
expos
region
allow
access
ab
without
interfer
bind
intact
viru
reveal
high
bind
affin
five
fold
mab
compar
bind
three
mab
jrfl
equival
viral
concentr
e
ngml
figur
differenti
bind
mab
intact
virion
could
also
attribut
number
potenti
nglycosyl
site
png
within
region
png
jrfl
respect
virus
overal
result
suggest
epitop
recogn
three
mab
expos
jrfl
howev
mab
abl
bind
jrfl
due
subtypec
specif
bind
activ
mab
test
assess
capac
neutral
panel
eleven
tier
virus
differ
subtyp
use
standard
tzmbl
cell
assay
mab
show
effect
neutral
two
subtypea
subtypec
five
tier
virus
one
viru
subtypec
six
tier
virus
neutral
two
mab
rel
low
effici
tabl
none
indian
mab
abl
neutral
subtypeb
virus
despit
antibodi
show
cross
reactiv
bind
nevertheless
number
virus
test
limit
contrast
mab
reach
neutral
titer
virus
test
consist
previou
studi
human
monoclon
antibodi
envelop
glycoprotein
use
tool
structur
function
analysi
viral
envelop
crucial
role
guid
design
prophylact
antihiv
vaccin
despit
huge
expans
subtypec
worldwid
cladec
virus
remain
one
least
studi
subtyp
especi
term
neutral
antibodi
use
rational
previou
studi
show
virus
gpgq
residu
tip
crown
envelop
induc
potent
cross
reactiv
nab
compar
virus
gpgr
motif
gener
three
mab
indian
donor
presum
infect
subtypec
virus
bear
gpgq
crown
function
analysi
ab
gener
reveal
potent
neutral
potenti
tier
virus
activ
limit
tier
virus
test
ab
select
ebvtransform
bcell
cultur
infect
antiretrovir
drug
patient
use
fusion
protein
advantag
use
conform
constrain
instead
linear
peptid
select
mab
cultur
anim
immunogen
previous
demonstr
found
mean
transform
well
posit
bind
first
screen
characterist
natur
bcell
infect
subject
condit
use
immort
appar
affect
number
type
abproduc
cell
line
grow
overal
posit
percentag
ab
secret
cultur
well
rel
good
could
attribut
high
titer
ab
reactiv
correspond
plasma
contrast
high
percentag
posit
secretor
initi
screen
abl
stabil
three
ab
produc
bcell
clone
loss
could
part
due
outgrowth
nonsecretor
b
cell
secretor
b
cell
subsequ
step
secondari
screen
cell
fusion
dilut
clone
process
moreov
b
cell
infect
patient
mostli
dysfunct
polyclon
activ
properti
associ
low
persist
ebv
infect
amino
acid
sequenc
variat
across
variou
subtyp
often
relat
differenti
immun
respons
focus
expect
origin
due
subtyp
specif
conform
differ
region
instanc
crown
residu
gpgq
nonclad
b
gpgr
clade
b
virus
respect
major
determin
ab
bind
neutral
epitop
map
ab
overlap
peptid
reveal
core
epitop
lie
crown
region
inde
recent
immunolog
structur
studi
mab
observ
similar
pattern
bind
wherein
essenti
mab
bind
residu
crown
two
mab
show
bind
subtypea
c
subtypeb
deriv
protein
peptid
mab
display
cross
reactiv
bind
subtypeb
well
bind
pattern
context
clade
specif
cross
reactiv
antibodi
two
mab
similar
bind
polyclon
plasma
antibodi
respect
patient
howev
differ
mab
context
plasma
ab
patient
figur
find
highlight
import
prescreen
plasma
bind
peptid
differ
viral
subtyp
prior
isol
mab
one
plausibl
reason
nonbind
mab
peptid
contrast
correspond
polyclon
plasma
may
attribut
higher
number
subtypec
specif
bcell
clone
b
cell
repertoir
patient
indic
high
bind
figur
may
also
partli
ascrib
bias
select
ctb
construct
contain
sequenc
might
allow
preferenti
pick
b
cell
clone
cladec
specif
interestingli
mab
show
cladea
c
common
gpgq
crown
motif
specif
bind
use
variabl
heavi
chain
gene
wherea
cross
reactiv
mab
use
differ
vh
gene
tabl
find
suggest
possibl
associ
antibodi
gene
usag
epitop
specif
howev
number
mab
gener
studi
small
comparison
remark
recent
analysi
antihiv
ab
point
preferenti
usag
gene
usag
ab
prefer
later
shown
defin
conserv
antigen
structur
within
ab
access
nativ
viru
often
challeng
glycosyl
pattern
epitop
mask
effect
particularli
recogn
region
wherein
neighbor
region
includ
shield
epitop
recogn
ab
although
studi
suggest
loop
remain
access
virus
howev
inform
limit
subtypeb
virus
remain
explor
subtyp
consist
bind
protein
jrfl
three
mab
abl
bind
intact
nativ
virion
similar
bind
pattern
figur
result
suggest
epitop
well
expos
intact
trimer
virus
jrfl
find
highli
support
previou
work
literatur
rational
use
protein
correspond
virus
intact
virion
bind
assay
minim
effect
loop
sequenc
neighbor
region
local
global
orient
subsequ
bind
ab
mab
show
potent
neutral
activ
subtypea
c
tier
virus
howev
activ
restrict
tier
especi
subtypeb
virus
find
intrigu
given
abil
mab
bind
two
repres
intact
virion
subtypeb
jrfl
subtypec
yet
fail
reach
neutral
titer
howev
note
mab
display
better
affin
show
neutral
though
reach
neutral
titer
virus
data
shown
overal
data
suggest
higher
concentr
mab
may
effect
neutral
howev
need
confirm
detail
togeth
result
suggest
effect
concentr
bind
neutral
may
vari
substanti
high
affin
bind
mab
might
critic
neutral
data
highli
support
variou
studi
conduct
previous
isol
three
mab
infect
donor
india
effect
neutral
tier
virus
less
effect
tier
virus
howev
need
confirm
test
broader
panel
virus
differ
subtyp
studi
demonstr
import
prescreen
plasma
ab
cross
reactiv
bind
product
mab
idea
likewis
employ
antigen
region
also
studi
highlight
signific
antibodi
affin
may
probabl
equal
import
epitop
access
effect
viral
neutral
furthermor
analysi
mab
gener
studi
allow
us
identifi
epitop
uniqu
clade
c
virus
also
share
subtyp
context
loop
data
may
provid
use
inform
vaccin
design
studi
approv
ethic
committe
india
institut
medic
scienc
aiim
new
delhi
written
inform
consent
research
public
data
obtain
particip
thirtythre
seroposit
drug
naiv
patient
male
femal
within
age
rang
year
median
year
recruit
studi
region
std
teach
train
research
centr
safdarjang
hospit
new
delhi
india
period
patient
median
count
rang
cellscub
millimet
addit
file
tabl
whole
blood
sampl
posit
donor
collect
edta
vacutain
plasma
separ
centrifug
g
store
aliquot
use
plasma
sampl
heat
inactiv
h
use
assay
patient
previous
shown
high
titer
ab
plasma
good
proport
direct
ab
display
cross
reactiv
andrabi
et
al
submit
presum
patient
infect
subtypec
virus
major
subtyp
india
inde
envelop
sequenc
partial
envelop
patient
reveal
major
patient
infect
subtypec
virus
andrabi
et
al
submit
mab
gener
use
cellular
techniqu
previous
describ
briefli
peripher
blood
mononuclear
cell
pbmc
ebv
transform
plate
cultur
polyclon
b
cell
activ
cpg
enhanc
ebv
infect
b
cell
transform
well
contain
abproduc
cell
identifi
test
cultur
supernat
bind
activ
cell
well
test
posit
expand
fuse
heteromyeloma
cell
line
atcc
catalog
fuse
cell
continu
make
function
ab
repeatedli
clone
monoclon
achiev
ab
purifi
cultur
supernat
use
protein
g
affin
column
ge
healthcar
concentr
mab
determin
noncommerci
elisa
mab
gener
previous
clade
b
infect
individu
mab
specif
parvoviru
use
control
ab
studi
nucleotid
sequenc
ig
variabl
gene
human
mab
determin
previous
describ
messeng
rna
extract
hybridoma
cell
line
produc
mab
revers
transcrib
cdna
use
oligo
dt
primer
amplif
variabl
fragment
perform
pcr
use
differ
gene
familyspecif
set
primer
cdna
templat
five
forward
primer
vh
gtg
cag
ctg
gtg
cag
tct
gtc
aac
tta
agg
gag
tct
gtg
cag
ctg
gtg
gag
tct
gtg
cag
ctg
cag
gag
tcg
gta
cag
ctg
cag
cag
tca
locat
end
v
gene
revers
primer
locat
end
jh
segment
nucleotid
constant
region
igg
pcr
amplif
perform
use
cycl
program
min
cycl
follow
min
ethidium
bromidestain
agaros
gel
use
visual
pcr
product
band
appropri
size
excis
clean
geneelut
minu
etbr
spin
column
sigma
usa
pcr
product
sequenc
macrogen
south
korea
direct
use
primer
appli
amplif
sequenc
data
analyz
use
intern
immunogenet
imgt
inform
system
http
imgtcinesfr
five
recombin
repres
sequenc
primari
isol
clade
b
c
produc
cell
protein
purchas
immun
technolog
corp
new
york
ny
set
linear
overlap
peptid
amino
acid
overlap
amino
acid
walk
correspond
sequenc
consensu
subtypec
cef
control
peptid
pool
pp
cat
obtain
nih
aid
research
refer
reagent
program
nih
arrrp
two
full
length
peptid
correspond
consensusb
ctrpnnntrksihigpgrafyttgeiigdirqahc
conc
ctrpnnntrksirigpgqtfyatgdiigdirqahc
conc
mper
dllaldswknlwnwfditnwlwyik
conc
idr
lgiwgcsgklicttavpwn
peptid
select
lo
alamo
sequenc
databas
http
hivlanlgov
synthes
sigma
genosi
usa
peptid
hplc
purifi
puriti
base
inform
provid
compani
toxin
b
ctb
fusion
protein
wild
type
ctb
wtctb
use
screen
antibodi
cultur
kindli
provid
prof
susan
zolla
pazner
new
york
univers
school
medicin
bind
activ
mab
protein
peptid
includ
overlap
peptid
test
enzymelink
immunosorb
assay
elisa
describ
briefli
elisa
plate
coat
overnight
protein
peptid
block
bovin
serum
albumin
bsa
pb
incub
mab
concentr
rang
dilut
bound
mab
detect
incub
alkalin
phosphataseconjug
goat
antihuman
igg
specif
southernbiotech
birmingham
al
follow
ad
substrat
develop
color
plate
read
nm
rel
affin
mab
determin
measur
concentr
mab
requir
maxim
bind
defin
bind
curv
reach
satur
level
describ
bind
mab
intact
virion
determin
captur
assay
previous
describ
briefli
plate
coat
overnight
goat
antihuman
immunoglobulin
g
igg
fc
ab
sigma
human
mab
satur
level
ad
h
incub
plate
block
bsa
phosphatebuff
salin
pb
contain
goat
serum
human
iggml
cultur
supernat
contain
pseudotyp
virus
jrfl
concentr
ngml
two
fold
dilut
primari
isol
start
concentr
ng
ad
plate
incub
overnight
room
temperatur
virus
captur
immobil
mab
lyse
tritonx
pb
step
assay
plate
wash
pb
contain
tween
ph
viru
lysat
quantifi
use
commerci
elisa
ab
subtypeb
viru
known
sensit
ab
use
assay
control
human
mab
use
neg
control
eleven
subtyp
b
c
virus
includ
five
primari
isol
jrcsf
six
pseudotyp
virus
jrfl
use
studi
primari
virus
envelop
clone
obtain
nih
arrrp
isol
expand
one
cycl
growth
phytohemagglutinin
pha
stimul
pbmc
describ
previous
avoid
alter
env
sequenc
due
multipl
round
expans
pseudotyp
virus
produc
cotransfect
revenv
express
plasmid
envdefici
backbon
vector
exponenti
divid
cell
atcc
catalog
tissu
cultur
plate
corn
inc
use
calcium
phosphat
promega
inc
method
pseudoviruscontain
cultur
supernat
harvest
hour
post
transfect
filter
pore
size
store
ml
aliquot
tissu
cultur
infecti
dose
determin
tzmbl
cell
neutral
virus
mab
measur
reduct
luciferas
gene
express
singl
round
infect
cell
also
known
tzmbl
cell
nih
arrrp
catalog
virus
briefli
pseudoviru
preincub
hr
flatbottom
cultur
plate
serial
dilut
mab
start
freshli
trypsin
tzmbl
cell
cell
growth
medium
contain
deae
dextran
proteas
inhibitor
indianavir
case
primari
isol
ad
well
mabviru
mixtur
duplic
one
set
control
well
receiv
cell
plu
pseudoviru
viru
control
anoth
set
receiv
cell
background
control
hour
incub
luciferas
activ
measur
use
brightglo
luciferas
assay
system
promega
inc
inhibitori
concentr
mab
determin
rel
luminesc
unit
rlu
reduc
compar
viru
control
well
author
declar
compet
interest
ra
kl
design
studi
perform
data
analysi
draft
manuscript
rp
ss
help
studi
design
mb
ab
nw
recruit
infect
patient
ra
carri
major
experi
rk
pk
help
plasmid
amplif
pseudotypedviru
gener
immunoglobulin
variabl
gene
sequenc
determin
dilut
clone
experi
respect
author
read
approv
final
manuscript
